Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis
Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana
Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana
View: Text | PDF
Research Article Pulmonology

Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosis

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. The role of the developmental transcription factor Sine oculis homeobox homolog 1 (SIX1) in the pathophysiology of lung fibrosis is not known. IPF lung tissue samples and IPF-derived alveolar type II cells (AT2) showed a significant increase in SIX1 mRNA and protein levels, and the SIX1 transcriptional coactivators EYA1 and EYA2 were elevated. Six1 was also upregulated in bleomycin-treated (BLM-treated) mice and in a model of spontaneous lung fibrosis driven by deletion of Telomeric Repeat Binding Factor 1 (Trf1) in AT2 cells. Conditional deletion of Six1 in AT2 cells prevented or halted BLM-induced lung fibrosis, as measured by a significant reduction in histological burden of fibrosis, reduced fibrotic mediator expression, and improved lung function. These effects were associated with increased macrophage migration inhibitory factor (MIF) in lung epithelial cells in vivo following SIX1 overexpression in BLM-induced fibrosis. A MIF promoter–driven luciferase assay demonstrated direct binding of Six1 to the 5′-TCAGG-3′ consensus sequence of the MIF promoter, identifying a likely mechanism of SIX1-driven MIF expression in the pathogenesis of lung fibrosis and providing a potentially novel pathway for targeting in IPF therapy.

Authors

Cory Wilson, Tinne C.J. Mertens, Pooja Shivshankar, Weizen Bi, Scott D. Collum, Nancy Wareing, Junsuk Ko, Tingting Weng, Ram P. Naikawadi, Paul J. Wolters, Pascal Maire, Soma S.K. Jyothula, Rajarajan A. Thandavarayan, Dewei Ren, Nathan D. Elrod, Eric J. Wagner, Howard J. Huang, Burton F. Dickey, Heide L. Ford, Harry Karmouty-Quintana

×

Figure 8

Overexpression of SIX1 in AT2 cells worsens lung fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Overexpression of SIX1 in AT2 cells worsens lung fibrosis.
(A) Represent...
(A) Representative model of the SIXTET;SPCrtTA (AT2-SIX1OE) genetics using the surfactant protein C (SPC) reverse tetracycline transcriptional activator (rtTA) driver under the control of doxycycline. (B) Western blot of isolated AT2 cells from wildtype C57BL/6 mice (WT) and the 4 possible genotypes used for the generation of the AT2-SIX1OE mice treated with 14 days of 625 mg/kg doxycycline — in order from 1–4, respectively — from C57BL/6, AT2-SIX1OE only, SPC-rtTA only, and AT2-SIX1OE. (C) RNA in situ hybridization of SPC-rtTA control mice and AT2-SIX1OE showing expression of Six1 (pink) in AT2-SIX1OE mice following doxycycline treatment. Scale bar: 20 μm. (D) Lung Six1 expression levels from BLM-treated SPC-rtTA and AT2-SIX1OE mice. (E) Kaplan-Meier survival curve showing percent survival of AT2-SIX1OE and SPC-rtTA challenged with i.p. BLM for 33 days. (F–J) Representative Masson’s trichrome stained lungs (F) (scale bar: 100 μm), Ashcroft scores (G) and qPCR for Col1a1 (H), Col1a2 (I), and Fn (J) from BLM-treated SPC-rtTA and AT2-SIX1OE mice. *P ≤ 0.05 and **P ≤ 0.01 by Student’s t tests with Welch correction. n = 12 for all data panels except G (n = 7) for SPC-rtTA BLM groups; n = 7 for all data panels except G (n = 14) for BLM-SIXTET group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts